|
|
BioSerenTach has the following innovative three DDS technologies.
The possible clients are pharmaceutical companies.
BioSerenTach performs pre-clinical study and clinical phase I study
with the clients.
|
Dissolving Microneedle (DM) chip
DM is a novel transdermal DDS. DM is composed of water-soluble thread-forming
polymer and drug that exists as solid dispersion or suspension. 100-300
microneedles are formed on a chip, 1.0 c㎡, where the length is 500μm and
the diameter of the base is 300μm. As polymer, chondroitin sulfate, sodium
hyarulonate, dextran and albumin are used. Drug is localized at the acral
portion of microneedles. After insertion into the skin by pressing with
a finger, polymer dissolves in the epiderm and drug is immediately released
and absorbed into the systemic circulation. As a drug, vaccine antigen, insulin, erythropoietin (EPO), interferon (IFN)
and growth hormone (GH) are recommended.
see details of our technologies
|
|
Three-layered microcapsules
For a long-term sustained-release injection preparation of leuprolide acetate, insulin, calcitonin, IFN, EPO, G-CS and GH etc
Microcapsules composed of three layers, (1)
surface layer, (2) drug-carrying layer and
(3) basement, have been developed. The surface
layer has a function of controlling the release
rate of drug. By selecting the compostion
of the surface layer, long-term sustained-release
injection preparation, for example one month,
is prepared. Feasibility study was performed with EPO, leuprolide acetate and low molecular
weight heparin (LMWH) with poly-ε-caprolactone and sustained-release charactersitics
for about 10 days was ascertained in rat experiments. BioSerenTach is now
developing a machine to produce three-layered microcapsules. |
|
Copyright BioSerenTach Inc, 2021
|
|
|
